The antibiotics markets: The total world market is in the range of $25 billion a year and it is growing, at a time when the antibiotics pipeline is “bone dry”.
The Schwiezer/Zhanel technology offers an important new opportunity with the aminoglycoside molecules; a class well established for its effectiveness and well understood safety profile.
Aminoglycosides constitute a large family of clinically important antibiotics They have broad spectrum activity against most Gram-negative and Gram-positive bacteria and have proven useful over decades. Although they exhibit potent bactericidal activity, their widespread use has been compromised by dose related toxicity and the emergence of aminoglycoside-resistant strains. Efforts to develop novel, active and less toxic aminoglycosides or modified analogues have been slow because they are difficult to chemically modify.
The Technology: provides a series of patented chemical modifications and conjugates. These are shown to be active in clinically important bacterial strains:
Composition of matter patents: special aminoglycoside – lipid and aminoglycoside-ultra short peptide conjugates
Practical methods of synthesis, cost effective and strong intellectual property “space”.
In vitro data on effectiveness with important bacterial strains, MRSA and Pseudomonas.spp.
Good in vitro toxicity profiles
For a detailed description download the Tech-op here
Tech ID
Inventors
Patent Status
License Status
80.02.676
Dr. Frank Schweizer, Chemistry
Dr. George Zhanel, Clinical Microbiology - Chair of Canadian Antimicrobial Resistance Alliance
University of Manitoba
Hydrophobically Enhanced Aminoglycosides : PCT/US20O9/50131
Aminoglycoside – peptide conjugates.: PCT/IB2008/003486
Worldwide, exclusive
This patent portfolio is available for licensing to qualified development partners.